Ethics, evidence, and cost in newborn screening.
When deciding what disorders to screen newborns for, we should be guided by evidence of real effectiveness, take opportunity cost into account, distribute costs and benefits fairly, and respect human rights. Current newborn screening policy does not meet these requirements.
Baily
Mary Ann
MA
The Hastings Center, USA.
Murray
Thomas H
TH
D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D030342:Genetic Diseases, Inborn / Q000175:diagnosis; D036281:Genetic Research / Q000941:ethics; D006078:Government Programs; D006806:Human Rights; D006801:Humans; D007231:Infant, Newborn; D008484:Medicaid; D008922:Mississippi; D015997:Neonatal Screening / Q000191:economics* / Q000941:ethics*; D010661:Phenylketonurias / Q000175:diagnosis; D016730:Program Development; D015397:Program Evaluation; D014481:United States